These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26387747)

  • 41. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.
    Tarkun I; Cetinarslan B; Türemen E; Sahin T; Cantürk Z; Komsuoglu B
    Eur J Endocrinol; 2005 Jul; 153(1):115-21. PubMed ID: 15994753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
    Trolle B; Lauszus FF; Frystyk J; Flyvbjerg A
    Fertil Steril; 2010 Nov; 94(6):2234-8. PubMed ID: 20189560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.
    Essah PA; Arrowood JA; Cheang KI; Adawadkar SS; Stovall DW; Nestler JE
    Fertil Steril; 2011 Aug; 96(2):501-504.e2. PubMed ID: 21733508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling.
    Kocak I; Ustün C
    J Obstet Gynaecol Res; 2006 Jun; 32(3):292-8. PubMed ID: 16764619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
    Tan S; Hahn S; Benson S; Dietz T; Lahner H; Moeller LC; Schmidt M; Elsenbruch S; Kimmig R; Mann K; Janssen OE
    Eur J Endocrinol; 2007 Nov; 157(5):669-76. PubMed ID: 17984248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.
    Jakubowska J; Bohdanowicz-Pawlak A; Milewicz A; Szymczak J; Bednarek-Tupikowska G; Demissie M
    Gynecol Endocrinol; 2008 Jul; 24(7):378-84. PubMed ID: 18645710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
    Morin-Papunen L; Rautio K; Ruokonen A; Hedberg P; Puukka M; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4649-54. PubMed ID: 14557435
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
    Nascimento AD; Silva Lara LA; Japur de Sá Rosa-e-Silva AC; Ferriani RA; Reis RM
    Gynecol Endocrinol; 2013 Mar; 29(3):246-9. PubMed ID: 23194004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome.
    Palomba S; Falbo A; Russo T; Manguso F; Tolino A; Zullo F; De Feo P; Orio F
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3128-35. PubMed ID: 17519312
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
    Kilic S; Yilmaz N; Zulfikaroglu E; Erdogan G; Aydin M; Batioglu S
    Gynecol Endocrinol; 2011 Sep; 27(9):622-9. PubMed ID: 21105835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome].
    Cheng X; Guo J; Xie J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Dec; 35(12):1389-91. PubMed ID: 25623461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF; Nilas L; Madsbad S; Holst JJ
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
    Meyer C; McGrath BP; Teede HJ
    Diabetes Care; 2007 Mar; 30(3):471-8. PubMed ID: 17327307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome.
    Sahin Y; Yirmibeş U; Keleştimur F; Aygen E
    Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):214-20. PubMed ID: 15063963
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascular endothelial growth factor and insulin-like growth factor-1 in polycystic ovary syndrome and their relation to ovarian blood flow.
    Abd El Aal DE; Mohamed SA; Amine AF; Meki AR
    Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):219-24. PubMed ID: 15653207
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
    Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D
    Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
    Koiou E; Tziomalos K; Katsikis I; Delkos D; Tsourdi EA; Panidis D
    Hormones (Athens); 2013; 12(4):559-66. PubMed ID: 24457404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.